Van ECK Associates Corp reduced its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 35.5% in the 3rd quarter, according to the company in its most recent 13F filing with the ...

How much a stock's price changes over time is a significant driver for most investors. Not only can price performance impact your portfolio, but it can help you compare investment results across ...

Halozyme's Q3 earnings exceeded expectations, with a $1.27 EPS and 34% YoY revenue growth, driven by ENHANZE tech and strong ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. Featuring daily updates ...

Halozyme Therapeutics, Inc. (HALO) shares are up after record revenue growth, improved guidance, and expansion plans.

Halozyme Therapeutics Inc (HALO) reports a 34% revenue increase, raises full-year guidance, and expands partnerships despite ...

JMP Securities analyst Jason Butler has reiterated their bullish stance on HALO stock, giving a Buy rating yesterday. Jason Butler has given ...

Verdence Capital Advisors LLC lifted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 1.9% in the third quarter, according to the company in its most recent 13F ...

Analysts anticipate Halozyme Therapeutics to report an earnings per share (EPS) of $0.98. Investors in Halozyme Therapeutics ...

In a report released yesterday, Brendan Smith from TD Cowen maintained a Buy rating on Halozyme (HALO – Research Report), with a price ...

What if you'd invested in Halozyme Therapeutics (HALO) ten years ago? It may not have been easy to hold on to HALO for all that time, but if you did, how much would your investment be worth today?